FilingSEC EDGAR8-K
Milestone Pharmaceuticals Receives NMPA Approval for Etripamil Nasal Spray in China
· SEC accepted
StageRegulatory Approval
Filing content
The company received approval from China's NMPA for etripamil nasal spray to treat PSVT, triggering a $2.0 million milestone payment.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…